NEW YORK, Dec 18 - DNA Sciences said Monday it had entered an agreement to acquire PPGx, a pharmacogenomics products and services company, in an all stock deal.

In a statement DNA Sciences, which collects and studies DNA samples for disease-relevant SNPs, said that the combined companies would integrate their different scientific methodologies and research programs and pool patient sample collections.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.